

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07H 17/02, A61K 31/70</b>		A2	(11) International Publication Number: <b>WO 95/16695</b>
			(43) International Publication Date: <b>22 June 1995 (22.06.95)</b>
(21) International Application Number: <b>PCT/EP94/03840</b>		(81) Designated States: AU, BY, CA, CN, FI, HU, JP, KR, KZ, NO, NZ, PL, RU, UA, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: <b>21 November 1994 (21.11.94)</b>			
(30) Priority Data: <b>9325417.5 13 December 1993 (13.12.93) GB</b>		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(71) Applicant: PHARMACIA S.P.A. [IT/IT]; Via Robert Koch, 1.2, I-20152 Milan (IT).			
(72) Inventors: BARGIOTTI, Alberto; Via Donati, N. 8, I-20146 Milan (IT). CARUSO, Michele; Via Desiderio, N. 3, I-20131 Milan (IT). GRANDI, Maria; Piazza 5 Giornate, N. 6, I-20131 Milan (IT). RIPAMONTI, Marina; Via Fulvio Testi, N. 91, I-20131 Milan (IT). SUARATO, Antonio; Via degli Imbriani, 39, I-20158 Milan (IT).			
(74) Agents: FRIGNOLI, Luigi et al.; Ing. A. Giambrocco & C.s.r.l., Via Rosolino Pilo, 19/b, I-20129 Milan (IT).			

(54) Title: 3'-AZIRIDINO-ANTHRACYCLINE DERIVATIVES



(1)



(2)

(57) Abstract

Anthracycline glycosides of general formulae (1) and (2), wherein  $R_1$  is hydrogen or a methoxy group;  $R_2$  is hydrogen, a hydroxy group or represents an acyloxy residue of formula (3):  $-O-COR_3$  wherein  $R_3$  is a linear or branched  $C_1-C_8$  alkyl, an aryl group or a heterocyclic mono or bicyclic ring, each of which may be unsubstituted or substituted with (a) an amino group  $NR_6R_7$  in which  $R_6$  and  $R_7$  are independently hydrogen or  $C_1-C_4$  alkyl or (b) a carboxy group;  $R_3$  and  $R_4$  both represent hydrogen or one of  $R_3$  and  $R_4$  is hydrogen and the other is hydroxy group or a group of formula  $-OSO_2R_5$  in which  $R_5$  may be a linear or branched alkyl group containing from 1 to 6 carbon atoms or an aryl group unsubstituted or substituted by 1 to 3 substituents each of which may independently be a linear or branched alkyl or alkoxy group of from 1 to 6 carbon atoms, a halogen atom or a nitro group; and pharmaceutically acceptable salts thereof; are active as antitumor agents.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

3'-AZIRIDINO-ANTHRACYCLINE DERIVATIVES


The invention relates to novel anthracycline glycosides endowed with antitumor activity, to processes for their preparation and to pharmaceutical compositions containing them.

The invention provides anthracycline glycosides, related to daunorubicin and doxorubicin, in which the 3'-amino group of the sugar residue is enclosed in an aziridino ring and, optionally, the hydroxy group at C-4' of the sugar may be protected in the form of a sulphonate. The invention also provides water soluble derivatives and pharmaceutically acceptable acid addition salts thereof.

The present invention provides a compound which is an anthracycline glycoside of formula 1 or 2:



wherein  $R_1$  is hydrogen or methoxy group;  $R_2$  is hydrogen, a hydroxy group or represents an acyloxy residue of formula 3:



- 5 wherein  $R_5$  is a linear or branched  $C_1$ - $C_8$  alkyl, a mono or bicyclic aryl, preferably phenyl, or a hetero mono or bicyclic ring, preferably pyridyl, each of which groups may optionally be substituted with (a) an aminogroup  $\text{-NR}_6\text{R}_7$  in which  $R_6$  and  $R_7$   
10 are independently hydrogen or  $C_1$ - $C_4$  alkyl or (b), a carboxy group;  $R_3$  and  $R_4$  both represent hydrogen or one of  $R_3$  and  $R_4$  is hydrogen and the other is a hydroxy group or a group of formula  $\text{-OSO}_2\text{R}_8$  in which  $R_8$  may be a linear or branched alkyl group  
15 containing from 1 to 6 carbon atoms, for example 1 to 4 carbon atoms;  $R_8$  may in particular be methyl, ethyl, n-propyl or isopropyl.

Alternatively,  $R_8$  may be an aryl group such as phenyl, unsubstituted or substituted by 1 to 3  
20 substituents each of which may independently be a linear or branched alkyl or alkoxy group of from 1 to 6 carbon atoms for example from 1 to 3 carbon atoms, a halogen atom or a nitro group. Examples of halogen atoms include fluorine, chlorine, bromine

and iodine, preferably fluorine or chlorine, more preferably chlorine.

In the present invention, an aryl group is a monocyclic or bicyclic aromatic hydrocarbon of 6 to 10 carbon atoms, for example phenyl or naphthyl. A heterocyclic ring is a 5- or 6-membered saturated or unsaturated heterocyclyl ring, containing at least one hetero atom selected from O, S and N, which is optionally fused to a second 5- or 6-membered, saturated or unsaturated heterocyclyl group.

Examples of saturated and unsaturated heterocyclic rings include pyrazolyl, imidazolyl, pyridyl, pyrazyl, pirimidyl, pyridazynyl, morpholino, thiomorpholino, furyl and thienyl rings.

Preferably  $R_2$  is hydroxy or O-nicotinyl,  $R_3$  is hydroxy or  $-OSO_2R_8$  where  $R_8$  is  $C_1$ - $C_4$  alkyl, and  $R_4$  is hydrogen.

Examples of compounds of the invention include:

(1a) 3'-deamino-3'-[1-aziridinyl]-4-O-methansulfonyl daunorubicin ( $R_1=OCH_3$ ,  $R_4=H$ ,  $R_3=OSO_2CH_3$ )


- (1b) 4-demethoxy-3'-deamino-3'-[1-aziridinyl]-4'-O-methansulfonyl daunorubicin ( $R_1=R_4=H$ ,  $R_3=OSO_2CH_3$ )
- (1c) 3'-deamino-3'-[1-aziridinyl]-daunorubicin ( $R_1=OCH_3$ ,  $R_4=H$ ,  $R_3=OH$ )
- 5 (1d) 4-demethoxy-3'-deamino-3'-[1-aziridinyl]-daunorubicin ( $R_1=R_4=H$ ,  $R_3=OH$ )
- (2a) 3'-deamino-3'-[1-aziridinyl]-4'-O-methansulfonyl-14-nicotinate-doxorubicin ( $R_1=OCH_3$ ,  $R_2=O$ -nicotinoyl,  $R_4=H$ ,  $R_3=OSO_2CH_3$ )
- 10 (2b) 3'-deamino-3'-[1-aziridinyl]-14-nicotinate-doxorubicin ( $R_1=OCH_3$ ,  $R_2=O$ -nicotinoyl,  $R_4=H$ ,  $R_3=OH$ )
- (2c) 3'-deamino-3'-[1-aziridinyl]-4'-O-methansulfonyl doxorubicin ( $R_1=OCH_3$ ,  $R_2=OH$ ,  $R_4=H$ ,  $R_3=OSO_2CH_3$ )
- 15 (2d) 4-demethoxy-3'-deamino-3'-[1-aziridinyl]-4'-O-methansulfonyl doxorubicin ( $R_1=R_4=H$ ,  $R_2=OH$ ,  $R_3=OSO_2CH_3$ )
- 20 (2e) 3'-deamino-3'-[1-aziridinyl]-doxorubicin ( $R_1=OCH_3$ ,  $R_4=H$ ,  $R_2=R_3=OH$ )
- (2f) 4-demethoxy-3'-deamino-3'-[1-aziridinyl]-doxorubicin ( $R_1=R_4=H$ ,  $R_2=R_3=OH$ )
- (2g) 3'-deamino-3'-[1-aziridinyl]-4'-iododoxorubicin ( $R_1=OCH_3$ ,  $R_2=OH$ ,  $R_4=H$ ,  $R_3=I$ )
- 25

(2h) 3'-deamino-3'-[1-aziridinyl]-4'-deoxydoxorubicin ( $R_1=\text{OCH}_3$ ,  $R_2=\text{OH}$ ,  $R_3=R_4=\text{H}$ )

and pharmaceutically acceptable salts thereof such as hydrochloride salts.


5 Further, the present invention provides a process for the preparation of an aziridino anthracycline glycoside of formula 1 or 2 as above defined or pharmaceutically acceptable salt thereof, which process comprises:

10 (a) converting an anthracycline of general formula 4:



wherein  $R_1$ ,  $R_3$  and  $R_4$  are as defined above and  $R_9$  represents a sulfonate group or halogen atom, preferably a chlorine atom, into an anthracycline of formula 1, the compound of formula 4 preferably being dissolved in an anhydrous organic solvent in the presence of an anhydrous alkali metal salt and a mild base; and, if desired,

(b) hydrolizing a derivative of formula 5



in which  $R_1$ ,  $R_3$ ,  $R_4$  are as defined above (which may be prepared from a compound of formula 1 following the procedure as described in US Patent No. 3,803,124) to obtain an aziridino anthracycline derivative of formula 2 in which  $R_2$  is a hydroxy group; and, if desired,

(c) reacting a compound of formula 5 as defined above with a salt derivative of formula 3'

25



7




in which  $R_5$  has the same meaning as above, with the proviso that  $R_5$  does not represent a residue bearing a primary amino group, and  $X^+$  represents an ion, preferably a sodium or potassium ion, and, if desired, converting the compound of formula 2 thus obtained into a pharmaceutically acceptable salt thereof; or

(d) reacting a compound of formula 5 as above defined with a salt derivative of formula 3' in which  $R_5$  is a primary amino group masked with an acid sensitive protecting group, then deblocking the protecting group and, if desired, converting the compound of formula 2 thus obtained into a pharmaceutically acceptable salt thereof.

The present invention provides another process for the preparation of an aziridino anthracycline glycoside of formula 2 as above defined or a pharmaceutically acceptable salt thereof, which process comprises:

(a) treating an anthracycline of general formula 6



wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$  and  $R_9$  are as defined above  
 [such compounds have also been disclosed in WO  
 93/01201], with silica gel and, if desired,  
 converting the compound of formula 2 thus obtained  
 into a pharmaceutically acceptable salt thereof.

It is of note that anthracyclines of formula 4  
 or 6 are also capable of forming the aziridino ring  
 when treated with silica gel. Mild conditions may  
 be used for this treatment which allows the  
 preparation of compounds of formula 2 starting from  
 basic sensitive ester derivatives such as those of  
 formula 6.

According to the present invention, preferably  
 the reaction conditions for preparing aziridino  
 anthracyclines of formula 1 comprise dissolving a  
 compound of formula 4, as previously defined, in an  
 anhydrous organic solvent, such as anhydrous  
 methylene chloride, in the presence of an anhydrous

alkali salt, for example anhydrous sodium or potassium carbonate or hydrogen carbonate, with stirring at a temperature of from 0 to 30°C, preferably at room temperature, and for from 15  
5 minutes to two hours, preferably for about 30 minutes.

In another process, compounds of formula 4 are dissolved in a mixture of organic solvents, such as dry methylene chloride and methanol from 1:1 to 1:3  
10 by volume, then the solution is treated with silica gel, preferably 230-400 mesh, with stirring at a temperature of from 0°C to 30°C, preferably at room temperature, and for from 15 minutes to two hours, preferably for about 30 minutes.

15 In a similar process, reaction conditions for transforming compounds of formula 6, as defined above, into aziridino anthracyclines of formula 2 preferably comprise dissolving compounds of formula 6 in an anhydrous organic solvent, such as dry  
20 methylene chloride and methanol, and treating the resultant solution with silica gel, preferably 230-400 mesh, with stirring at a temperature of from 0 to 30°C, preferably at room temperature for from 15 minutes to two hours, preferably for about 30  
25 minutes.

The use of a polar solvent, such as methanol, in the silica gel procedure is used in order to remove the anthracycline from the silica.

In another process for the preparation of an  
5 aziridino anthracycline glycoside of formula 2 or a pharmaceutically acceptable salt thereof, wherein  $R_2$  is a group of formula 3 in which  $R_5$  does not represent a residue bearing a primary amino group, preferable reaction conditions comprise reacting a  
10 compound of formula 5 with an acid salt derivative of formula 3' as previously defined, in anhydrous polar solvent, preferably acetone or dimethylformamide, at a temperature of from 20 to 60°C, preferably at room temperature, for from 4 to  
15 15 hours, preferably 5 to 12 hours.

Reaction conditions for preparing an aziridino anthracycline glycoside of general formula 2, wherein  $R_2$  represents a group of formula 3 in which  $R_5$  is a primary amino group, comprises reacting  
20 compounds of formula 5, as defined above, with an acid salt derivative of formula 3' in which the amino group is protected with an acid sensitive group, for example the amino group is protected with Schiff's base, in a polar aprotic solvent such  
25 as acetone or dimethylformamide, at a temperature

of from 20 to 60°C, preferably at room temperature,  
for from 4 to 15 hours, preferably 5 to 12 hours,  
then the resultant (N-protected)-ester derivative  
is deblocked by dissolving it in e.g. methylene  
5 chloride and adding distilled water and aqueous  
hydrochloric acid preferably about the same volume  
of water as methylene chloride and hydrochloric  
acid in an amount which corresponds to  
approximately three equivalents of 0.1N HCl. The  
10 mixture is stirred vigorously at a temperature of  
from 0 to 20°C, preferably at about 15°C, for from  
30 minutes to two hours, preferably 45 to 90  
minutes, separated and the aqueous phase is dry  
frozen to obtain the soluble ammonium hydrochloride  
15 salt of a C-15 ester derivative of formula 2.  
Preferably, the primary amino group is protected  
with a methylenediphenyl group.

As a further aspect, the invention provides  
pharmaceutical compositions comprising an  
20 anthracycline glycoside of formula 1 or 2 or a  
pharmaceutically acceptable salt thereof in  
combination with a pharmaceutically acceptable  
diluent or carrier.

Conventional carriers and diluents may be used. The compositions may be formulated and administered in a conventional manner.

Suitable routes of administration include  
5 parenteral administration. For parenteral administration a liquid formulation may be prepared using the active compound and a sterile diluent or carrier which may either dissolve the active compound or provide a suspension for it. The  
10 parenteral formulation may be prepared in the form of a sterile solid for reconstitution prior to administration with a suitable vehicle such as physiological saline, sterile water or other sterile vehicle.

15 The compounds of the invention are useful in methods of treatment of the human and animal body by therapy. They are useful as anti-tumor agents in particular in the treatment of leukaemia or colon adenocarcinoma. A therapeutically effective amount  
20 is administered to a patient having a tumor to ameliorate or improve the condition of the patient. An amount sufficient to inhibit the growth of the tumor may be administered.


The dosage to be given can be ascertained  
25 using known dosage ranges for doxorubicin and

daunorubicin modified by reference to the activity shown by the present compounds *in vitro* and *in vivo* anti-tumor tests. Suitable dosages are generally in the range of 1 to 200 mg/m<sup>2</sup> body surface, preferably from 1 to 100 mg/m<sup>2</sup>, depending on the nature and severity of the disease being treated and on the general condition of the patient.

The following examples illustrate the invention.

10 Example 1

Preparation of 3'-deamino-3'-[1-aziridinyl]-4'-O-methanesulfonyl daunorubicin



3'-N-(2-chloroethyl)-4'-O-methanesulfonyl-

15 daunorubicin (4a,  $R_1 = \text{OCH}_3$ ,  $R_4 = \text{H}$ ,  $R_3 = \text{OSO}_2\text{CH}_3$ ,  $R_9 = \text{Cl}$ ) (0.33 g, 0.05 mmol), prepared as described in WO/93/012001 was dissolved in a mixture of anhydrous methylene chloride (10 ml) and methanol (20 ml) and stirred with silica gel (Merck, 200-400 mesh, 2g)  
20 at room temperature for 30 minutes. The solution was then filtered, concentrated to dryness and the crude material flash chromatographed on a silica gel column using a mixture of methylene chloride and methanol (95:5 by volume) as the eluting system  
25 to give the title compound 1a (yield 0.22 g).

14

TLC on Kieselgel Plates F254 (Merck), using the eluting system methylene chloride and methanol (98:2 by volume)  $R_f=0,65$ .

FD-MS:  $m/z$  [M+] 631.

5 2H-NMR (400 MHz,  $CDCl_3$ )  $\delta$ ;  
1.16, 1.25 (m, 2H, aziridine hydrogens); 1.36 (d,  $J=6.4$ Hz, 3H,  $CH_3-5'$ ); 1.52 (m, 1H,  $H-3'$ ); 1.73 (m, 2H, aziridine hydrogens); 1.80 (m, 1H,  $H-2'eq$ ); 2.09 (m, 1H,  $H-2'ax$ ); 2.12 (m, 1H,  $H-8ax$ ); 2.31 (m, 1H,  $H-8eq$ ); 2.39 (s, 3H,  $COCH_3$ ); 2.98 (d,  $J=19.2$ Hz, 1H,  $H-10ax$ ); 3.21 (dd,  $J=1.7, 19.2$ Hz, 1H,  $H-10eq$ ); 3.22 (s, 3H,  $CH_3SO_2$ ); 4.09 (q,  $J=6.4$ Hz, 1H,  $H-5'$ ); 4.10 (s, 3H,  $OCH_3$ ); 4.44 (s, 1H,  $OH-9$ ); 4.75 (s, 1H,  $H-4'$ ); 5.28 (m, 1H,  $H-7$ ); 5.55 (d,  $J=3.4$ Hz, 1H,  $H-1'$ ); 7.41 (d,  $J=8.1$ Hz, 1H,  $H-3$ ); 7.80 (dd,  $J=7.7, 8.1$ Hz, 1H,  $H-2$ ); 8.05 (d,  $J=7.7$ Hz, 1H,  $H-1$ ); 13.30 (s, 1H,  $OH-11$ ); 14.00 (s, 1H,  $OH-6$ ).

#### Example 2

Preparation of 4-demethoxy-3'-deamino-3'-[1-  
20 aziridinyl]-4'-O-methansulfonyl daunorubicin

(1b:  $R_1=R_4=H$ ,  $R_3=OSO_2CH_3$ )

4-demethoxy-N-(2-hydroxyethyl)daunorubicin

(4b:  $R_1=R_4=H$ ,  $R_3=OSO_2CH_3$ ,  $R_9=OH$ , 0.3 g, 0.5 mmol)  
was dissolved in a mixture of methylene chloride  
25 (10 ml) and methanol (5 ml) and shaken at room



temperature with silica gel (3 g) for 30 minutes. The organic solution was then filtered and the solvent removed under reduced pressure. The residue was flash chromatographed on a silica gel column using a mixture of methylene chloride and methanol (95:5 by volume) as the eluting system to give the title compound 1b (0.18 g). TLC on Kieselgel Plates F254 (Merck), using the eluting system methylene chloride and methanol (20:1 by volume)

10 Rf=0.42.

FD-MS: m/z [M+] 601.

### Example 3

#### Preparation of 3'-deamino-3'-[1-aziridinyl]-4'-O-methansulfonyl-14-nicotinate-doxorubicin

15 (2a:  $R_1=OCH_3$ ,  $R_2=O\text{-}nicotinoyl$ ,  $R_4=H$ ,  $R_3=OSO_2CH_3$ ).

3'-deamino-3'-[1-aziridinyl]-4'-O-methansulfonyl-daunorubicin (1a, 0.63 g, 1 mmole), prepared as described in Example 1, was dissolved in a mixture of anhydrous methanol (6 ml) and dioxane (13 ml), ethyl orthoformate (0.5 ml) was added and then the mixture was treated with a solution of bromine (1 g) in anhydrous methylene chloride (5 ml) at 10°C for 1.5 hours. The reaction mixture was then precipitated with a mixture of

20

25

16

ethyl ether (100 ml) and petroleum ether (50 ml). The precipitate was collected and redissolved in a mixture of acetone (15 ml) and 0.25N aqueous hydrogen bromide (15 ml). The mixture was kept at 30°C for 20 hours, then extracted with n-butanol (50 ml). The organic solvent was removed under reduced pressure and the residue, dissolved in dry acetone (200 ml) was treated with potassium nicotinate (2g) at reflux for one hour. The solvent was removed under reduced pressure and the crude material was chromatographed on a silica gel column using a mixture of methylene chloride and methanol (95:5 by volume) as the eluting system to give the title compound 2a (0.35 g). m.p. 148-149°C with decomposition. TLC on Kieselgel Plate F254 (Merck), using the eluting system methylene chloride and methanol (10:1 by volume).

Rf=0.37.

FD-MS: m/z [M+] 752.

20 Example 4

Preparation of 3'-deamino-3'-[1-aziridinyl]-4'-O-methansulfonyl doxorubicin

(2c: R<sub>1</sub>=OCH<sub>3</sub>, R<sub>2</sub>=OH, R<sub>4</sub>=H, R<sub>3</sub>=OSO<sub>2</sub>CH<sub>3</sub>)

3'-N-(2-chloroethyl)-4'-methansulfonyldoxo-

25 rubicin (6a: R<sub>1</sub>=OCH<sub>3</sub>, R<sub>2</sub>=OH, R<sub>9</sub>=Cl, R<sub>3</sub>=OSO<sub>2</sub>CH<sub>3</sub>,

## 17.

$R_4=H$ ), prepared as described in GB 9114549, is converted into the title compound 2c as described in Example 1. TLC on Kieselgel Plates F254 (Merck), using the eluting system methylene chloride and acetone (8:2 by volume)

Rf=0.35.

FD-MS: m/z [M+] 647.

Example 5

10 Preparation of 3'-deamino-3'-[1-aziridinyl]-4'-iododoxorubicin

(2g:  $R_1=OCH_3$ ,  $R_2=OH$ ,  $R_4=H$ ,  $R_3=I$ ).

3'-N-(2-chloroethyl)-4'-iododoxorubicin (6b:  $R_1=OCH_3$ ,  $R_2=OH$ ,  $R_9=Cl$ ,  $R_3=I$ ,  $R_4=H$ ), prepared as described in GB 9114549, is converted into the title compound 2g as described in Example 1. TLC on Kieselgel Plates F254 (Merck), using the eluting system methylene chloride and acetone (9:1 by volume) Rf=0.45.

FD-MS: m/z [M+] 679.

20 Example 6

Preparation of 3'-deamino-3'-[1-aziridinyl]-4'-deoxydoxorubicin

(2h:  $R_1=OCH_3$ ,  $R_2=OH$ ,  $R_3=R_4=H$ ).

3'-N-(2-chloroethyl)-4'-deoxydoxorubicin (6c:

$R_1 = \text{OCH}_3$ ,  $R_2 = \text{OH}$ ,  $R_3 = \text{Cl}$ ,  $R_3 = R_4 = \text{H}$ ), prepared as described in GB 9114549, is converted into the title compound 2h as described in Example 1. TLC on Kieselgel Plates F254 (Merck), using the eluting  
5 system methylene chloride and acetone (20:1 by volume)  $R_f = 0.33$ .

FD-MS:  $m/z$  [M+] 553.

Biological activity

3'-deamino-3'-[1-aziridinyl]-4'-O-methansul-fonyl  
10 daunrorubicin (1a),  
4-demethoxy-3'-deamino-3'-[1-aziridinyl]-4'-O-methansulfonyl daunorubicin (1b),  
3'-deamino-3'-[1-aziridinyl]-4'-O-methansulfonyl-  
14-nicotinate-doxorubicin (2a) and  
15 3'-deamino-3'-[1-aziridinyl]-4'-O-methansulfonyl  
doxorubicin (2c), were tested *in vitro* on two human cell lines, LoVo (colon adenocarcinoma) and LoVo/DX (colon adenocarcinoma resistant to doxorubicin) in comparison with doxorubicin.

20 The citotoxic activity is reported as IC<sub>50</sub>, the concentration inhibiting 50% of colony formation, calculated on concentration response curves. Resistance index R.I. is the ratio between the IC<sub>50</sub> on resistant cells and the IC<sub>50</sub> on  
25 sensitive cells. Compounds 1a, 1b, 2a and 2c showed

high activity against both cell lines and had a low resistance index (Table I).

Compounds 1a, 1b, 2a and 2c were also evaluated *in vivo* against P388 murine leukaemia resistant to doxorubicin ( $10^5$  cell/mouse transplanted i.v. in BD2F1 mice) in comparison with doxorubicin.

Compounds 1a, 1b, 2a and 2c also showed strikingly higher activity than doxorubicin (Table II).

**TABLE 1:** *in vitro* cytotoxic activity (IC<sub>50</sub>) of compounds 1a, 1b, 2a and 2c on LoVo and LoVo/DX cells in comparison with doxorubicin.

compound	IC <sub>50</sub> (ng/ml) <sup>(1)</sup>		
	LoVo	LoVo/DX	R.I. <sup>(2)</sup>
<u>1a</u>	13	22	1.7
<u>1b</u>	27	26	0.9
<u>2a</u>	14	40	2.9
<u>2c</u>	2.7	24	9.2
<u>doxorubicin</u>	82.5	4975	60.3

Colony assay: 4 h treatment

(1) IC<sub>50</sub> = concentration inhibiting 50% colony formation

(2) R.I. = Resistance Index = (IC<sub>50</sub> LoVo/DX)/(IC<sub>50</sub> LoVo)

**TABLE 2:** Antitumor activity of compounds 1a, 1b, 2a and 2c on P388/DX leukaemia in comparison with doxorubicin.

5

compound	O.D. <sup>(1)</sup> (mg/kg)	T/C <sup>(2)</sup> %
<u>1a</u>	2.2	190
<u>1b</u>	3.8	240
<u>2a</u>	2.5	200
<u>2c</u>	1.8	195
doxorubicin	16.9	106


The compounds were suspended in Tween 80 (10%) and injected i.v. one day after tumor transplantation.

(1) Optimal Dose


(2) Median survival time of treated mice/Median survival time of controls x 100.

## CLAIMS

1. A compound which is an anthracycline glycoside of formula 1 or 2:



wherein R<sub>1</sub> is hydrogen or methoxy group; R<sub>2</sub> is hydrogen, a hydroxy group or represents an acyloxy residue of formula 3



wherein R<sub>5</sub> is a linear or branched C<sub>1</sub>-C<sub>8</sub> alkyl, a mono or bicyclic aryl group or a hetero mono or bicyclic ring, each of which may be substituted with:

20 (a) an aminogroup  $-NR_6R_7$  in which  $R_6$  and  $R_7$  are  
independently hydrogen or  $C_1$ - $C_4$  alkyl or

(b) a carboxy group;

R<sub>3</sub> and R<sub>4</sub> both represent hydrogen or one of R<sub>3</sub> and R<sub>4</sub> is hydrogen and the other is a hydroxy group or

25 a group of formula  $-\text{OSO}_2\text{R}_8$  in which  $\text{R}_8$  may be a

linear or branched alkyl group containing from 1 to 6 carbon atoms or an aryl group which is unsubstituted or substituted by 1 to 3 substituents each of which may independently be a linear or branched alkyl or alkoxy group of from 1 to 6 carbon atoms, a halogen atom or a nitro group; or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1, wherein R<sub>5</sub> is phenyl.

10 3. A compound according to claim 1, wherein R<sub>5</sub> is pyridyl.

4. A compound according to any one of claims 1 to 3, wherein R<sub>8</sub> is methyl, ethyl, n-propyl or isopropyl.

15 5. A compound according to any one of claims 1 to 3, wherein R<sub>8</sub> is a phenyl group unsubstituted or substituted by 1 to 3 substituents each of which may independently be a linear or branched alkyl or alkoxy group of from 1 to 3  
20 carbon atoms.

6. A compound according to claim 1, which is:


3'-deamino-3'-[1-aziridinyl]-4'-O-methansulfonyl  
daunorubicin;



- 4-demethoxy-3'-deamino-3'-[1-aziridinyl]-4'-O-methansulfonyl daunorubicin;  
3'-deamino-3'-[1-aziridinyl]-daunorubicin;  
4-demethoxy-3'-deamino-3'-[1-aziridinyl]-daunorubi-  
5 cin;  
3'-deamino-3'-[1-aziridinyl]-4'-O-methansulfonyl-  
14-nicotinate-doxorubicin;  
3'-deamino-3'-[1-aziridinyl]-14-nicotinate-doxoru-  
bicin;  
10 3'-deamino-3'-[1-aziridinyl]-4'-O-methansulfonyl  
doxorubicin;  
4-demethoxy-3'-deamino-3'-[1-aziridinyl]-4'-O-methansulfonyl doxorubicin;  
3'-deamino-3'-[1-aziridinyl]-doxorubicin;  
15 4-demethoxy-3'-deamino-3'-[1-aziridinyl]-doxorubi-  
cin;  
3'-deamino-3'-[1-aziridinyl]-4'-iododoxorubicin;  
3'-deamino-3'-[1-aziridinyl]-4'-deoxydoxorubicin.  
7. A compound according to claim 1 which is  
20 3'-deamino-3'-[1-aziridinyl]-4'-O-methansulfonyl  
daunorubicin;  
4-demethoxy-3'-deamino-3'-[1-aziridinyl]-4'-O-methansulfonyl daunorubicin; or  
3'-deamino-3'-[1-aziridinyl]-4'-O-methansulfonyl-  
25 14-nicotinate-doxorubicin.

8. A compound according to any one of the preceding claims which is in the form of its hydrochloride salt.

9. A process for the preparation of an  
5 anthracycline glycoside of formula 1 or a pharmaceutically acceptable salt thereof as defined in claim 1, which process comprises converting an anthracycline glycoside of general formula 4



wherein  $R_1$ ,  $R_3$  and  $R_4$  are as defined in claim 1 and  $R_9$  represents a sulfonate group or halogen atom,  
20 into an anthracycline glycoside of formula 1 and, if desired, converting the anthracycline glycoside of formula 1 thus obtained into a pharmaceutically acceptable salt thereof.

10. A process according to claim 9, which  
25 is carried out in an anhydrous organic solvent in

the presence of an anhydrous alkali salt and a mild base.

11. A process according to claim 10, wherein the anhydrous organic solvent is anhydrous methylene chloride.

12. A process according to claim 10 or 11, wherein the anhydrous alkali salt is anhydrous sodium or potassium carbonate or hydrogen carbonate.

13. A process according to any one of claims 9 to 12, wherein process (a) is conducted at a temperature of from 0°C to 30°C or 15 minutes to 2 hours.


14. A process for the preparation of an anthracycline glycoside of formula 1 or a pharmaceutically acceptable salt thereof as defined in claim 1, which process comprises treating an anthracycline glycoside of general formula 4 as defined in claim 9 with silica gel to obtain an anthracycline glycoside of formula 1 and, if desired, converting the anthracycline glycoside of formula 1 thus obtained into a pharmaceutically acceptable salt thereof.

15. A process for the preparation of an anthracycline glycoside of formula 2 as defined in

claim 1, or a pharmaceutically acceptable salt thereof, which process comprises treating an anthracycline glycoside of general formula 6

5

10



wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>9</sub> are as defined in claim 9, with silica gel and, if desired, converting the anthracycline glycoside of formula 2 thus obtained into a pharmaceutically acceptable salt thereof.


16. A process according to claim 14 or 15, wherein the compound of formula 4 is dissolved in an anhydrous polar organic solvent which is dry methylene chloride, methanol or a mixture thereof.

17. A process according to claim 16 in which the solvent is a mixture of dry methylene chloride and methanol from 1:1 to 1:3 v/v.

18. A process according to any one of claims 14 to 17 which is carried out with stirring at a temperature of from 0°C to 30°C for 15 minutes to two hours.

5 19. A process according to any one of claims 14 to 18, wherein particles of the silica gel range between 230 and 400 mesh.

20. A process for preparing an anthracycline glycoside of formula 2 or  
10 pharmaceutically acceptable salt thereof as defined in claim 1, which process comprises hydrolizing a derivative of formula 5



in which R<sub>1</sub>, R<sub>3</sub> and R<sub>4</sub> are as defined in claim 1, to obtain an anthracycline glycoside of formula 2 as defined in claim 1, in which R<sub>2</sub> is a hydroxy group; or reacting a derivative of formula 5 as  
25 defined above with a salt derivative of formula 3'



in which  $R_5$  is as defined in claim 1, with the proviso that  $R_5$  does not represent a residue bearing a primary amino group and  $X^+$  represents an ion, and, if desired, converting the anthracycline glycoside of formula 2 thus obtained into a pharmaceutically acceptable salt thereof; or reacting a derivative of formula 5 as above defined with a salt derivative of formula 3' bearing a primary amino group masked with an acid sensitive protecting group, then deblocking the amino protecting group and, if desired, converting the anthracycline glycoside of formula 2 thus obtained into a pharmaceutically acceptable salt thereof.

21. A process according to claim 20 in which  $X^+$  is a sodium or potassium ion.

22. A process for the preparation of an anthracycline glycoside of formula 2 or a pharmaceutically acceptable salt thereof as defined in claim 1, wherein  $R_2$  is a group of formula 3 in which  $R_5$  does not represent a residue bearing a primary amino group, which process comprises reacting a derivative of formula 5 as defined in claim 20 with an acid salt derivative of formula 3', as defined in claim 20, in an anhydrous polar

solvent at a temperature from 20°C to 60°C for 4 to 15 hours.

23. A process according to claim 22 wherein the anhydrous polar solvent is acetone or dimethyl  
5 formamide.

24. A process for the preparation of an anthracycline glycoside of formula 2 or a pharmaceutically acceptable salt thereof, as defined in claim 1, wherein R<sub>2</sub> represents a group  
10 of formula 3 bearing a primary amino group, which process comprises reacting an acid salt derivative of formula 3' as defined in claim 20 in which the amino group is protected with an acid sensitive group, in a polar aprotic solvent at a temperature  
15 from 20°C to 60°C for 4 to 15 hours, then deblocking the resultant (N-protected)-ester derivative by dissolving it in an organic solvent, and adding distilled water and aqueous hydrochloric acid, under stirring at a temperature from 0°C to  
20 20°C for 30 minutes to two hours, separating and dry freezing the aqueous phase, thus obtaining a soluble ammonium hydrochloride salt of the corresponding C-14 ester derivative of formula 2 as defined in claim 1.

25. A process according to claim 24 wherein the acid sensitive group is methylene diphenyl and the organic solvent used in the deblocking step is methylene chloride.

5           26. A process according to claim 24 or 25, wherein the polar aprotic solvent is acetone or dimethylformamide.

          27. A compound as claimed in claim 1 specifically as defined herein.

10           28. A process for preparing a compound as defined in claim 1 which process is substantially as described herein in Example 1 to 3.

          29. A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier  
15 and, as an active principle, an anthracycline glycoside of formula 1 or 2, or a pharmaceutically acceptable salt thereof, as defined in claim 1.

          30. An anthracycline glycoside of formula 1 or 2 or a pharmaceutically acceptable salt thereof,  
20 as defined in claim 1, for use in a method of treatment of the human or animal body by therapy.

          31. An anthracycline glycoside of a pharmaceutically acceptable salt thereof according to claim 30, for use as an anti-tumor agent.